MENU
+Compare
GNOM
ETF ticker: NASDAQ
AS OF
Jan 30, 04:59 PM (EDT)
Price
$10.22
Change
+$0.22 (+2.20%)
Net Assets
69.87M

GNOM stock forecast, quote, news & analysis

Category: @Health
GNOM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for GNOM with price predictions
Jan 29, 2025

GNOM saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for GNOM moved out of overbought territory on January 29, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 71 similar instances where the indicator exited the overbought zone. In of the 71 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

GNOM moved below its 50-day moving average on January 27, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GNOM broke above its upper Bollinger Band on January 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GNOM entered a downward trend on January 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 27, 2025. You may want to consider a long position or call options on GNOM as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GNOM just turned positive on January 21, 2025. Looking at past instances where GNOM's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Gilead Sciences (NASDAQ:GILD), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X Genomics & Biotechnology ETF ETF is 11.98B. The market cap for tickers in the group ranges from 73.4M to 113.7B. VRTX holds the highest valuation in this group at 113.7B. The lowest valued company is BLUE at 73.4M.

High and low price notable news

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -1%. For the same ETF, the average monthly price growth was 5%, and the average quarterly price growth was -8%. RNA experienced the highest price growth at 8%, while CRBU experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -30%. For the same stocks of the ETF, the average monthly volume growth was 26% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 67
Price Growth Rating: 61
SMR Rating: 92
Profit Risk Rating: 85
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
GNOM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Global X Funds600 Lexington Avenue, 20th FloorNew York
Phone
+1 8884938631
Web
www.globalxfunds.com